GKOS 241220 150.00P (GKOS241220P150000) Stock Options, News & Quotes

US OptionsDetailed Quotes

GKOS241220P150000

Watchlist

0.00
0.000.00%

15min DelayTrading Dec 12 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

J.P. Morgan Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $160
Moomoo NewsDec 12 07:33 ET · Ratings
Glaukos (GKOS) Receives a Buy From J.P. Morgan
TipRanksDec 12 07:06 ET · Ratings
Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $153
BenzingaDec 11 10:17 ET · Ratings
Here's Why You Should Add Glaukos Stock to Your Portfolio Now
Zacks Dec 11 08:00 ET
Glaukos Raised to Buy From Neutral by Citigroup
Dow JonesDec 11 07:39 ET · Ratings
Glaukos Price Target Raised to $162.00/Share From $132.00 by Citigroup
Dow JonesDec 11 07:39 ET · Ratings

Comments

Moomoo AI

Jan 21 08:51

Glaukos' revenue growth is the market's focus due to its unprofitability. The 88% share price gain is solid, not standout. Market sentiment is lukewarm, hinting at potential stronger growth trends. Recent sentiment is positive due to strong share price momentum.

Investors Bid Glaukos (NYSE:GKOS) up US$137m Despite Increasing Losses YoY, Taking One-year Return to 88%

Meltyy

Dec 19, 2023 01:33

PDUFA Update…

Last week’s PDUFAs:
$Arcutis Biotherapeutics (ARQT.US)$ : Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co (MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos (GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co (MRK.US)$ : Approved ...

Meltyy

Dec 4, 2023 01:48

PDUFA Events for December 2023

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics (CRSP.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $OptiNose (OPTN.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $Calliditas Therapeutics (CALT.US)$ $bluebird bio (BLUE.US)$ $Glaukos (GKOS.US)$ $Ionis Pharmaceuticals (IONS.US)$ $Amgen (AMGN.US)$ $Merck & Co (MRK.US)$

Moomoo AI

Nov 3, 2023 06:30

Glaukos' stock carries risk due to losses and high debt, despite cash reserves. The absence of EBIT level profits and free cash flow make sustainability questionable. Investors should proceed with caution.

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Rockhoundj

Nov 5, 2022 02:23

Let’s see if this bounces

$Glaukos (GKOS.US)$
im seeing some decent chart upside here
thoughts?